The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is clinical stage T2C prostate cancer intermediate- or high-risk disease?
Zachary Klaassen
No relevant relationships to disclose
Abhay A Singh
No relevant relationships to disclose
Lauren Howard
No relevant relationships to disclose
Martha K. Terris
No relevant relationships to disclose
William J Aronson
No relevant relationships to disclose
Matthew R. Cooperberg
No relevant relationships to disclose
Christopher L Amling
No relevant relationships to disclose
Christopher J Kane
No relevant relationships to disclose
Lionel Lloyds Banez
No relevant relationships to disclose
Stephen J. Freedland
No relevant relationships to disclose